Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BTRC
REST API REST API
Homo sapiens
BTRC is differentially expressed in 294 experiments: 145 organism parts: lung, heart, ... (143 more);, 223 disease states: normal, acute myeloid leukemia, ... (221 more);, 92 cell types 390 cell lines 44 compound treatments and 84 other conditions.
Synonyms Fwd1, betaTrCP, beta-TrCP1, bTrCP1, bTrCP, FBXW1A
Orthologs BTRC (Bos taurus)   Q86SD3_CIOIN (Ciona intestinalis)   Btrc (Rattus norvegicus)   BTRC (Gallus gallus)   Btrc (Mus musculus)   slmb (Drosophila melanogaster)   MET30 (Saccharomyces cerevisiae)   ENSXETG00000021199 (Xenopus laevis)   BTRC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, ligase activity, negative regulation of transcription, DNA-dependent, protein binding, cytoplasm, protein catabolic process, beta-catenin binding, protein ubiquitination, mitotic cell cycle, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process, SCF ubiquitin ligase complex, Wnt receptor signaling pathway, regulation of cell cycle, nucleus, protein polyubiquitination, ubiquitin-protein ligase activity, regulation of I-kappaB kinase/NF-kappaB cascade, signal transduction, positive regulation of transcription, DNA-dependent, positive regulation of proteolysis, ubiquitin-dependent protein catabolic process, mammary gland epithelial cell proliferation, viral reproduction, protein destabilization, protein phosphorylated amino acid binding, interspecies interaction between organisms, regulation of proteasomal protein catabolic process, branching involved in mammary gland duct morphogenesis, positive regulation of circadian rhythm, protein dephosphorylation, positive regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, cellular response to organic cyclic compound, regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
InterPro Term WD40_repeat_dom, WD40_repeat, F-box_dom_cyclin-like, WD40_repeat_2, G-protein_beta_WD-40_rep, Beta-TrCP_D, WD40_repeat_subgr
UniProt Accession Q9Y297, Q5T1W7, Q5W141, Q68DS0, B7Z3H4, Q86WI4
Search EB-eye ENSG00000166167
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
HepG2
2
E-GEOD-7307, E-GEOD-21154
BT474
1
2
E-MTAB-62, E-MEXP-440, E-MTAB-37
BDCM
1
E-MTAB-37
C7H2-S10
1
E-GEOD-22152
GM08930
1
E-TABM-321
384 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, ... (44 experiments)

Factor Value U/D Experiments
cardiac myocyte
2
E-TABM-145, E-AFMX-5
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD34+
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-GEOD-26672, E-MEXP-930
fibroblast
2
E-GEOD-3920, E-GEOD-26672
mononuclear
2
E-GEOD-13987, E-GEOD-26672
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (59 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
colon carcinoma
2
E-MTAB-62, E-MTAB-37
control
2
E-GEOD-16363, E-GEOD-8121
lung adenocarcinoma
2
E-MTAB-37, E-MEXP-231
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
217 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (26 experiments)

Factor Value U/D Experiments
none
4
7
E-GEOD-5824, E-GEOD-412, E-TABM-868, E-MEXP-1958, E-TABM-782, ... (11 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
SDF
1
E-GEOD-7307
no estradiol
1
E-GEOD-20081
4,5-dianilinophthalimide
2
1
E-GEOD-5258
chloroguine
1
E-GEOD-5418
38 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
not specified
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-22513, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-GEOD-22148, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-18005, E-TABM-868, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-MEXP-1220, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1493, E-GEOD-22309, E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.376 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM